An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535]).
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2012
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- 20 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2012 Results from a pooled analysis presented at the 2012 International Conference on Alzheimer's Disease.
- 21 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.